Literature DB >> 33279503

Serum sphingomyelin species profile is altered in hematologic malignancies.

Atsushi Hori1, Fumihiro Ishida2, Hideyuki Nakazawa3, Makoto Yamaura4, Sunao Morita5, Takeshi Uehara6, Takayuki Honda6, Hiroya Hidaka7.   

Abstract

Sphingomyelin (SM) plays key roles in regulating cell membrane fluidity and in intracellular signal transduction. However, little is known as to whether alterations in SM concentration or SM species distribution are linked pathological conditions. The present study examined SM concentrations and species profiles in serum taken from patients with hematologic malignancies. Serum was collected from normal subjects and from patients with B-cell lymphoma, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and acute lymphatic leukemia/ lymphoblastic lymphoma (ALL/LBL). Serum SM species distribution was analyzed using electrospray ionization mass spectrometry/ mass spectrometry (ESI MS/MS). Serum lipids concentration were measured using enzymatic assays. Normal and hematologic malignancy sera were similar in terms of total serum SM and phosphatidylcholine (PC) concentrations and SM/PC ratio. However, all hematologic malignancy sera had lower levels of SM species containing saturated odd chain fatty acids (OCFAs) in the side chain compared to normal serum. In addition, the proportion of SM species with saturated (C20 and C22) and mono unsaturated fatty acids (C18, C20, C22) were lower in MDS patient serum compared to normal serum. The present study revealed that the serum SM species profile in patients with hematologic malignancies differed from that of normal subjects despite total serum SM and PC concentrations and SM/PC ratios being similar between the various cancer groups and the normal group.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Electrospray ionization mass spectrometry; Fatty acid; Hematologic malignancies; Odd carbon fatty acid; Sphingomyelin

Mesh:

Substances:

Year:  2020        PMID: 33279503     DOI: 10.1016/j.cca.2020.11.024

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

Review 1.  Sphingolipids and Lymphomas: A Double-Edged Sword.

Authors:  Alfredo Pherez-Farah; Rosa Del Carmen López-Sánchez; Luis Mario Villela-Martínez; Rocío Ortiz-López; Brady E Beltrán; José Ascención Hernández-Hernández
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

Review 2.  Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.

Authors:  Johnson Ung; Su-Fern Tan; Todd E Fox; Jeremy J P Shaw; Luke R Vass; Pedro Costa-Pinheiro; Francine E Garrett-Bakelman; Michael K Keng; Arati Sharma; David F Claxton; Ross L Levine; Martin S Tallman; Myles C Cabot; Mark Kester; David J Feith; Thomas P Loughran
Journal:  Blood Rev       Date:  2022-04-09       Impact factor: 10.626

3.  Spatial metabolomics for evaluating response to neoadjuvant therapy in non-small cell lung cancer patients.

Authors:  Jian Shen; Na Sun; Philipp Zens; Thomas Kunzke; Achim Buck; Verena M Prade; Jun Wang; Qian Wang; Ronggui Hu; Annette Feuchtinger; Sabina Berezowska; Axel Walch
Journal:  Cancer Commun (Lond)       Date:  2022-05-20

4.  Untargeted metabolomics of newborn dried blood spots reveals sex-specific associations with pediatric acute myeloid leukemia.

Authors:  Lauren Petrick; Partow Imani; Kelsi Perttula; Yukiko Yano; Todd Whitehead; Catherine Metayer; Courtney Schiffman; Georgia Dolios; Sandrine Dudoit; Stephen Rappaport
Journal:  Leuk Res       Date:  2021-04-24       Impact factor: 3.715

5.  Cytokine Levels at Birth in Children Who Developed Acute Lymphoblastic Leukemia.

Authors:  Todd P Whitehead; Joseph L Wiemels; Mi Zhou; Alice Y Kang; Lucie S McCoy; Rong Wang; Briana Fitch; Lauren M Petrick; Yukiko Yano; Partow Imani; Stephen M Rappaport; Gary V Dahl; Scott C Kogan; Xiaomei Ma; Catherine Metayer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-06-02       Impact factor: 4.254

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.